Meta-analysis Of Serum Uric Acid Level As A Biomarker For COPD

Objective:To systematically evaluate the clinical significance of serum uric acid(s UA)in patients with chronic obstructive pulmonary disease(COPD).Methods:From the establishment of the database to December 2021,the computer searched Web of Science,Pub Med,Embase,Cochrane Library,CNKI,Wanfang Database,VIP Database,China Biomedical Literature Database(CBM)and other databases.A comprehensive collection of literature on blood uric acid(s UA)and COPD was conducted to evaluate the included literature according to the methods recommended by the Cochrane Systematic Review Manual.Studies eligible for meta-analysis must include two groups of participants,COPD patients and healthy controls.Eligible studies must report mean or median levels of serum uric acid and their standard deviation(SD)or interquartile spacing between participants in both groups.Meta-analysis was performed on case-control studies that met the inclusion criteria using Rev Man 5.4 software.Results:A total of 795 literatures were retrieved,and 13 studies that met the criteria were eventually included after screening,including 1148 stable COPD patients and 816 healthy control subjects.Meta-analysis showed that:(1)s UA in COPD group was higher than that in healthy control group(SMD = 1.31,95%CI = 0.84-1.77,P < 0.05).(2)s UA in GOLD grade 2 group was higher than that in GOLD Grade 1 group(SMD = 0.99,95%CI =0.54-1.45,P < 0.05),and the difference was statistically significant.(3)s UA in GOLD grade 3 group was higher than that in GOLD Grade 2 group(SMD = 0.68,95%CI =0.29-1.07,P < 0.05),the difference was statistically significant.(2)s UA in GOLD grade 4group was higher than that in GOLD Grade 4 group(SMD = 0.74,95%CI = 0.12-1.35,P <0.05).Conclusion:Current studies have found that serum uric acid levels in copd patients are significantly higher than those in non-COPD patients,and s UA levels show a progressively higher trend from GOLD grade 1 to GOLD Grade 4.Serum uric acid may be a useful biomarker for determining disease severity in stable COPD patients,but further studies are needed to confirm this finding.